Cor Vasa 2024, 66(6):599-607 | DOI: 10.33678/cor.2024.078

(Isolated cardiac sarcoidosis as a cause of out-of-hospital cardiac arrest - a case report and a review)

Volodymir Dudasha, Miloš Kubáneka, Petr Peichla, Ondřej Fabiánb, Theodor Adlac, David Zogalad, Martina Koziar Vašákováe, Alice Krebsováa, Marek Šramkoa, Adrian Reichenbacha, Jana Vrbskáa, Vojtěch Melenovskýa, Josef Kautznera
a Klinika kardiologie, Institut klinické a experimentální medicíny, Praha, Česká republika
b Pracoviště klinické a transplantační patologie, Institut klinické a experimentální medicíny a Ústav patologie a molekulární medicíny, 3. lékařská fakulta Univerzity Karlovy a Fakultní Thomayerova nemocnice, Praha, Česká republika
c Pracoviště zobrazovacích metod, Institut klinické a experimentální medicíny, Praha, Česká republika
d Ústav nukleární medicíny, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice v Praze, Praha, Česká republika
e Plicní klinika, 1. lékařská fakulta Univerzity Karlovy a Fakultní Thomayerova nemocnice, Praha, Česká republika

Isolated cardiac sarcoidosis is a rare disease with a challenging diagnostic process reflecting a low sensitivity of endomyocardial biopsy (EMB). Therefore, it often requires a multimodal imaging using cardiac magnetic resonance imaging (CMR) and/or positron emission tomography (PET-CT) with administration of 18Ffluordeoxyglucose (FDG). Its clinical manifestation includes advanced atrioventricular block, ventricular tachyar- rhythmias and congestive heart failure. We aimed to illustrate pitfalls in the diagnosis of clinically isolated cardiac sarcoidosis in a young male with an aborted cardiac arrest due to ventricular fibrillation. This case inspired us to provide an updated review of the management of cardiac sarcoidosis. Case description: A 28-year-old male without any comorbidities was admitted to our department after an aborted out-of-hospital cardiac arrest due to ventricular fibrillation in February 2022. His first electrocardiogram showed sinus rhythm and a complete atrioventricular block with left bundle branch block QRS morphology. Echocardiogram and coronary angiography revealed severe non-ischemic systolic dysfunction of the non-dilated left ventricle with an ejection fraction of 25%. Findings in EMB specimens were non-specific. A biventricular cardioverter-defibrillator was implanted due to a persistent complete atrioventricular block. Cardiac magnetic resonance imaging was not done from the safety reasons due to dependency of the subject on cardiac pacing and expected poor quality due to artefacts from the implanted electrodes. In March 2022, PET-CT with administration of FDG was performed. Unfortunately, the examination was not diagnostic due to an incomplete suppression of the metabolism of carbohydrates. However, three avid lymphatic nodes were detected in mediastinum. Repeated PET-CT was performed in July 2022 with successful suppression of the metabolism of carbohydrates. The examination revealed a mismatch between focally increased accumulation of FDG and absent perfusion in anteroapical, septal, and basal segments, which is a typical finding for an inflammatory cardiac disease. In addition, there was an obvious progression of lymphadenopathy both above and under the diaphragm. Subsequently, we performed a repeated EMB, which verified cardiac sarcoidosis. This suggested a diagnosis of isolated cardiac sarcoidosis at the time of disease manifestation. These results enabled to start immunosuppression with corticosteroids and azathioprine, which was tolerated without complications. A gradual improvement in left ventricular ejection fraction up to 45% was observed and documented in September 2023. The patient remains clinically stable in the functional class II, without interventions from the implanted cardioverter-defibrillator. Since March 2023, the patient is not dependent on cardiac pacing.

Conclusion: The diagnosis of cardiac sarcoidosis should be considered in patients with non-ischemic dysfunction of the left ventricle, especially if accompanied with aneurysms of cardiac ventricles. The suspicion rises in the presence of atrioventricular blocks or occurrence of ventricular tachyarrhythmias. The difficult diagnosis of isolated cardiac sarcoidosis can be established in selected cases by multimodal imaging including CMR and PET-CT, or repeated EMB. The correct diagnosis is important both due prognostic and therapeutic implications.

Keywords: AV block, Cardiac arrest

Received: August 5, 2024; Revised: September 16, 2024; Accepted: October 2, 2024; Prepublished online: June 2, 2012; Published: December 20, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dudash V, Kubánek M, Peichl P, Fabián O, Adla T, Zogala D, et al.. (Isolated cardiac sarcoidosis as a cause of out-of-hospital cardiac arrest - a case report and a review). Cor Vasa. 2024;66(6):599-607. doi: 10.33678/cor.2024.078.
Download citation

References

  1. Miedema J, Cinetto F, Smed-Sörensen A, Spagnolo P. The immunopathogenesis of sarcoidosis. J Autoimmun 2024 May 10:103247. Online ahead of print. Go to original source... Go to PubMed...
  2. Hajšl M, Sedloň P, Černohous M, et al. Sarkoidóza srdce jako příčina náhlé srdeční smrti. Cor Vasa 2013;55:e78-e81. Go to original source...
  3. Cooper LT. Cardiac sarcoidosis. In: Cooper LT (ed.). Myocarditis. From bench to bedside. Humana Press, Totowa, New Yersey, 2003:421-436. Go to original source...
  4. Kandolin R, Lehtonen J, Graner M, et al. Diagnosing isolated cardiac sarcoidosis. J Intern Med 2011;270:461-468. Go to original source... Go to PubMed...
  5. Kandolin R, Lehtonen J, Airaksinen J, et al. Cardiac sarcoidosis. Epidemiology, characteristics and outcome over 25 years in a nationwide study. Circulation 2015;131:624-632. Go to original source... Go to PubMed...
  6. Uemura A, Morimoto SI, Hiramitsu S, et al. Histologic diagnostic rate of cardiac sarcoidosis: Evaluation of endomyocardial biopsies. Am Heart J 1999;138:299-302. Go to original source... Go to PubMed...
  7. Ribeiro Neto ML, Jellis CL, Cremer PC, et al. Cardiac Sarcoidosis. Clin Chest Med 2024;45:105-118. Go to original source... Go to PubMed...
  8. Kupari M, Lehtonen J. POINT: Should Isolated Cardiac Sarcoidosis Be Considered a Significant Manifestation of Sarcoidosis? Yes. Chest 2021;160:36-38. Go to original source... Go to PubMed...
  9. Birnie DH, Nery PB, Beanlands RS. Counterpoint: should isolated cardiac sarcoidosis be considered a signficant manifestation of sarcoidosis? No. Chest 2021;160:38-42. Go to original source... Go to PubMed...
  10. Kupari M, Lehtonen J. Rebuttal From Drs Kupari and Lehtonen. Chest 2021;160:42-43. Go to original source... Go to PubMed...
  11. Birnie DH, Nery PB, Beanlands RS. Rebuttal from Drs Birnie, Nery, and Beanlands. Chest 2021;160:43-44. Go to original source... Go to PubMed...
  12. Juneau D, Nery P, Russo J, et al. How common is isolated cardiac sarcoidosis? Extra-cardiac and cardiac findings on clinical examination and whole-body F-fluorodeoxyglucose positron emission tomography. Int J Cardiol 2018;253:189-193. Go to original source... Go to PubMed...
  13. Simonen P, Lehtonen J, Kandolin R, et al. F-18- -fluorodeoxyglucose positron emission tomography-guided sampling of the mediastinal lymph nodes in the diagnosis of cardiac sarcoidosis. Am J Cardiol 2015;116:1581-1585. Go to original source... Go to PubMed...
  14. Rosenbaum AN, Kolluri N, Elwazir MY, et al. Identification of a novel presumed cardiac sarcoidosis category for patients at high risk of disease. Int J Cardiol 2021;335:66-72. Go to original source... Go to PubMed...
  15. Kawai H, Sarai M, Kato Y, et al. Diagnosis of isolated cardiac sarcoidosis based on new guidelines. Esc Heart Fail 2020;1:2662-2671. Go to original source... Go to PubMed...
  16. Giudicatti L, Marangou J, Nolan D, et al. The utility of whole body 18 F-FDG PET-CT in diagnosing isolated cardiac sarcoidosis: the western Australian cardiac sarcoid study. Heart Lung Circ 2020;29:e1-e6. Go to original source... Go to PubMed...
  17. Van Woensel J, Koopman B, Schiefer M, et al. Organ involvement in newly diagnosed sarcoidosis patients in the Netherlands: The first large European multicentre prospective study. Respir Med 2024;226:107608. Go to original source... Go to PubMed...
  18. Nery PB, Beanlands RS, Nair GM, et al. Atrioventricular block as the initial manifestation of cardiac sarcoidosis in middle-aged adults. J Cardiovasc Electrophysiol 2014;25:875-881. Go to original source... Go to PubMed...
  19. Kumar S, Barbhaiya C, Nagashima K, et al. Ventricular tachycardia in cardiac sarcoidosis. Characterisation of ventricular substrate and outcomes of catheter ablation. Circ Arrhythm Electrophysiol 2015;8:87-93. Go to original source... Go to PubMed...
  20. Petek BJ, Rosenthal DG, Patton KK, et al. Cardiac sarcoidosis: diagnosis confirmation by bronchoalveolar lavage and lung biopsy. Respir Med 2018;144:S13-S19. Go to original source... Go to PubMed...
  21. Aravena C, Almeida FA, Culver DA, et al. The utility of endobronchial ultrasound-transbronchial needle aspiration in patients with suspected extrapulmonary sarcoidosis without thoracic lymphadenopathy. Respir Med 2020;171:106074. Go to original source... Go to PubMed...
  22. Schupp JC, Freitag-Wolf S, Bargagli E, et al. Phenotypes of organ involvement in sarcoidosis. Eur Respir J 2018;51:1700991. Go to original source... Go to PubMed...
  23. Dubrey SW, Falk RH. Diagnosis and management of cardiac sarcoidosis. Prog Cardiovasc Dis 2010;52:336-346. Go to original source... Go to PubMed...
  24. Kron J, Ellenbogen KA. Cardiac sarcoidosis: Contemporary review. J Cardiovasc Electrophysiol 2015;26:104-109. Go to original source... Go to PubMed...
  25. Crouser ED, Maier LA, Wilson KC, et al. Diagnosis and detection of sarcoidosis an official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med 2020;201:e26-e51. Go to original source... Go to PubMed...
  26. Vita T, Okada DR, Veillet-Chowdhury M, et al. Complementary value of cardiac magnetic resonance imaging and positron emission tomography/computed tomography in the assessment of cardiac sarcoidosis. Circ Cardiovasc Imaging 2018; 11:e007030. Go to original source... Go to PubMed...
  27. Marschner CA, Aloufi F, Aitken M, et al. Combined FDG PET/MRI versus Standard-of-Care Imaging in the Evaluation of Cardiac Sarcoidosis. Radiol Cardiothorac Imaging 2023;5:e220292. Go to original source... Go to PubMed...
  28. Patel MR, Cawley PJ, Heitner JF, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation 2009;120:1969-1977. Go to original source... Go to PubMed...
  29. Schulz-Menger J, Wassmuth R, Abdel-Aty H, et al. Patterns of myocardial inflammation and scarring in sarcoidosis as assessed by cardiovascular magnetic resonance. Heart 2006;92:399-400. Go to original source... Go to PubMed...
  30. Aitken M, Chan MV, Fresno CU, et al. Diagnostic accuracy of cardiac MRI versus FDG PET for cardiac sarcoidosis: a systematic review and metaanalysis. Radiology 2022;304:566-579. Go to original source... Go to PubMed...
  31. Puntmann VO, Isted A, Hinojar R, et al. T1 and T2 Mapping in Recognition of Early Cardiac Involvement in Systemic Sarcoidosis. Radiology 2017;285:63-72. Go to original source... Go to PubMed...
  32. Ishida Y, Yoshinaga K. Recommendations for 18F-fluorodeoxyglucose positron emission tomography imaging for cardiac sarcoidosis: Japanese Society of Nuclear Cardiology Recommendations. Ann Nucl Med 2014;28:393-403. Go to original source... Go to PubMed...
  33. Atterton-Evans V, Nutrdiet B, Turner J, et al. Variances of dietary preparation for suppression of physiological 18 F-FDG myocardial uptake in the presence of cardiac sarcoidosis: a systematic review. J Nucl Cardiol 2020;27:481-489. Go to original source... Go to PubMed...
  34. Cheng VY, Slomka PJ, Ahlen M, et al. Impact of carbohydrate restriction with and without fatty acid loading on myocardial 18F-FDG uptake during PET: a randomized controlled trial. J Nucl Cardiol 2010;17:286-291. Go to original source... Go to PubMed...
  35. Harisankar CN, Mittal BR, Agrawal KL, et al. Utility of high fat and low carbohydrate diet in suppressing myocardial FDG uptake. J Nucl Cardiol 2011;18:926-936. Go to original source... Go to PubMed...
  36. Lu Y, Grant C, Xie K, Sweiss NJ. Suppression of myocardial 18F-FDG uptake through prolonged high-fat, high-protein, and very-low-carbohydrate diet before FDG-PET/CT for evaluation of patients with suspected cardiac sarcoidosis. Clin Nucl Med 2017;42:88-94. Go to original source... Go to PubMed...
  37. Ozutemiz C, Koksel Y, Froelich JW, et al. Comparison of the effect of three different dietary modifications on myocardial suppression in (18)F-FDG PET/CT evaluation of patients for suspected cardiac sarcoidosis. J Nucl Med 2021;62:1759-1767. Go to original source... Go to PubMed...
  38. Morooka M, Moroi M, Uno K, et al. Long fasting is effective in inhibiting physiological myocardial 18F-FDG uptake and for evaluating active lesions of cardiac sarcoidosis. EJNMMI Res 2014;4:1-11. Go to original source... Go to PubMed...
  39. Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease. A scientific statement from the American Heart Association , the American College of Cardiology, and the European Society of Cardiology. Circulation 2007;116: 2216-2233. Go to original source... Go to PubMed...
  40. Seferovic PM, Tsutsui H, McNamara DM, et al. Heart Failure Association, Heart Failure Society of America , and Japanese Heart Failure Society position statement on endomyocardial biopsy. J Card Fail 2021;27:727-743. Go to original source... Go to PubMed...
  41. Kupari M, Kandolin R, Lehtonen J, et al. Diagnosing isolated cardiac sarcoidosis. J Intern Med 2011;461-468. Go to original source... Go to PubMed...
  42. Nery PB, Keren A, Healey J, Leug E, et al. Isolated cardiac sarcoidosis: establishing the diagnosis with electroanatomic mapping-guided endomyocardial biopsy. Can J Cardiol 2013;29:1015.e1-3. Go to original source... Go to PubMed...
  43. Liang JJ, Hebl VB, DeSimone CV, et al. Electrogram guidance. A method to increase the precision and diagnostic yield of endomyocardial biopsy for suspected cardiac sarcoidosis and myokarditis JACC Heart Fail 2014;2:466-473. Go to original source... Go to PubMed...
  44. Ezzeddine FM, Kapa S, Rosenbaum A, et al. Electrogram- -guided endomyocardial biopsy yield in patients with suspected cardiac sarcoidosis and relation to outcomes. J Cardiovasc Electrophysiol 2021;32:2486-2495. Go to original source... Go to PubMed...
  45. Lehtonen JY, Jokinen JJ, Holmström M, Kupari M. Open chest core needle biopsy of left ventricle in the evaluation of suspected focal myocardial inflammation. J Thorac Cardiovasc Surg 2015;149:e99-e102. Go to original source... Go to PubMed...
  46. Hromaníková K, Kubánek M, Krebsová A, et al. Záchyt laminopatie s převažujícím postižením srdce v rámci předtransplantační diagnostiky - kazuistika, rozbor rizikové stratifikace a kardiologického managementu pacientů s laminopatií. Cor Vasa 2022;64:67-71. Go to original source...
  47. Kubánek M, Schimerová T, Piherová L, et al. Desminopathy: Novel Desmin Variants, a New Cardiac Phenotype, and Further Evidence for Secondary Mitochondrial Dysfunction. J Clin Med 2020;9:937. Go to original source... Go to PubMed...
  48. Judson MA, Costabel U, Drent M, et al. The WASOG sarcoidosis organ assessment instrument: an update of a previous clinical tool. Sarcoidosis Vasc Diffus Lung Dis 2014;31:19-27.
  49. Birnie DHS, Bobun F, Cooper J et al. HRS expert consensus statement on diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014;11:1305-1323. Go to original source... Go to PubMed...
  50. Terasaki F, Azuma A, Anzai T, et al. JCS 2016 guideline on diagnosis and treatment of cardiac sarcoidosis - digest version. Circ J 2019;83:2329-2388. Go to original source... Go to PubMed...
  51. Reza N, Levin MG, Vidula MK, et al. Prevalence of pathogenic variants in dilated cardiomyopathy-associated genes in patients evaluated for cardiac sarcoidosis. Circ Genomic Precis Med 2023;16:1-3. Go to original source... Go to PubMed...
  52. Lal M, Chen C, Newsome B, et al. Genetic cardiomyopathy masquerading as cardiac sarcoidosis. J Am Coll Cardiol 2023;81:9-11. Go to original source... Go to PubMed...
  53. Smith ED, Lakdawala NK, Papoutsidakis N, et al. Desmoplakin cardiomyopathy, a fibrotic and inflammatory form of cardiomyopathy distinct from typical dilated or arrhythmogenic right ventricular cardiomyopathy. Circulation 2020;141:1872-1884. Go to original source... Go to PubMed...
  54. Lehtonen J, Uusitalo V, Pöyhönen P, et al. Cardiac sarcoidosis: phenotypes, diagnosis, treatment, and prognosis. Eur Heart J 2023;44:1495-1510. Go to original source... Go to PubMed...
  55. Cheng RK, Kittleson MM, Beavers CJ, et al.; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology, and Council on Cardiovascular and Stroke Nursing. Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association. Circulation 2024;149:e1197-e1216. Go to original source... Go to PubMed...
  56. Yazaki Y, Isobe M, Hiroe M, et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol 2001;88:1006-1010. Go to original source... Go to PubMed...
  57. Okura Y, Dec GW, Hare JM, et al. A clinical and histopathologic comparison of cardiac sarcoidosis and idiopathic giant cell myocarditis. J Am Coll Cardiol 2003;41:322-329. Go to original source... Go to PubMed...
  58. Takaya Y, Nakamura K, Nishii N, Ito H. Clinical outcomes of patients with isolated cardiac sarcoidosis confirmed by clinical diagnostic criteria. Int J Cardiol 2021;345:49-53. Go to original source... Go to PubMed...
  59. Sink J, Joyce C, Liebo MJ, Wilber DJ. Long-Term Outcomes of Cardiac Sarcoid: Prognostic Implications of Isolated Cardiac Involvement and Impact of Diagnostic Delays. J Am Heart Assoc 2023;12:e028342. Go to original source... Go to PubMed...
  60. Ekström K, Lehtonen J, Nordenswan HK, et al. Sudden death in cardiac sarcoidosis: an analysis of nationwide clinical and cause-of-death registries. Eur Heart J 2019;40:3121-3128. Go to original source... Go to PubMed...
  61. Osborne MT, Hulten EA, Singh A, et al. Reduction in 18F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis. J Nucl Cardiol 2014;21:166-174. Go to original source... Go to PubMed...
  62. Gilotra N, Okada D, Sharma A, Chrispin J. Management of Cardiac Sarcoidosis in 2020. Arrhythm Electrophysiol Rev 2020;9:182-188. Go to original source... Go to PubMed...
  63. Obi ON. Anti-inflammatory Therapy for Sarcoidosis. Clin Chest Med 2024;45:131-157. Go to original source... Go to PubMed...
  64. Birnie D, Beanlands RSB, Nery P, et al. Cardiac sarcoidosis multi-center randomized controlled trial (CHASM CS-RCT). Am Heart J 2020;220:246-252. Go to original source... Go to PubMed...
  65. Baker MC, Sheth K, Witteles R, et al. TNF-alpha inhibition for the treatment of cardiac sarcoidosis. Semin Arthritis Rheum 2020;50:546-552. Go to original source... Go to PubMed...
  66. Sadek MM, Yung D, Birnie DH, et al. Corticosteroid therapy for cardiac sarcoidosis: A systematic review. Can J Cardiol 2013;29:1034-1041. Go to original source... Go to PubMed...
  67. Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Developed by The Task Force for the Management of Patients with Ventricular Arrhythmias And The Prevention Of Sudden Cardiac Death of the European Society of Cardiology (ESC). Eur Heart J 2022;43:3997-4126. Go to original source... Go to PubMed...
  68. Siontis KC, Santangeli P, Muser D, et al. Outcomes Associated With Catheter Ablation of Ventricular Tachycardia in Patients With Cardiac Sarcoidosis. JAMA Cardiol 2022;7:175-183. Go to original source... Go to PubMed...
  69. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022;24:4-131. Go to original source... Go to PubMed...
  70. Zaidi AR, Zaidi A, Vaitkus PT. Outcome of heart transplantation in patients with sarcoid cardiomyopathy. J Heart Lung Transplant 2007;26:714-717. Go to original source... Go to PubMed...

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.





Cor et Vasa

You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.